<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03480945</url>
  </required_header>
  <id_info>
    <org_study_id>AIDdiabetes</org_study_id>
    <nct_id>NCT03480945</nct_id>
  </id_info>
  <brief_title>Glycemic Control and Endothelial Function in Patients With Type 2 Diabetes</brief_title>
  <acronym>AIDdiabetes</acronym>
  <official_title>Evaluation of the Mechanism Underlying Endothelial Dysfunction in Patients With Type 2 Diabetes With Poor and Optimized Glycaemic Control</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Karolinska Institutet</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Karolinska Institutet</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study objective To evaluate the mechanism behind endothelial dysfunction in patients with&#xD;
      type 2 diabetes in relation to the level of glycaemic control.&#xD;
&#xD;
      Primary endpoint: Change in endothelium dependent vasodilatation (EDV).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study is performed on one group of patients with type 2 diabetes and one group of&#xD;
      age-matched healthy controls&#xD;
&#xD;
      Inclusion criteria:&#xD;
&#xD;
        1. Type 2 diabetes&#xD;
&#xD;
        2. Poor glycaemic control defined as a mean day blood glucose &gt;12 mmol/L.&#xD;
&#xD;
      Exclusion criteria:&#xD;
&#xD;
        1. Age &gt;80 years.&#xD;
&#xD;
        2. HbA1c &lt;70 mmol/mol&#xD;
&#xD;
        3. Myocardial infarction/unstable angina within 6 weeks prior to the study.&#xD;
&#xD;
        4. Treatment with oral anticoagulants (Warfarin or New oral anticoagulants)&#xD;
&#xD;
        5. Raynaud's phenomenon, peripheral vasculopathies, arterial shunting or other vascular&#xD;
           surgery of the study arm.&#xD;
&#xD;
        6. Any concomitant disease or condition that may interfere with the possibility for the&#xD;
           patient to comply with or complete the study protocol.&#xD;
&#xD;
        7. Participant in an ongoing study.&#xD;
&#xD;
        8. Unwillingness to participate following oral and written information.&#xD;
&#xD;
      Healthy controls Inclusion criteria&#xD;
&#xD;
      1. No medical history of cardiovascular disease 2. Fasting blood glucose &lt;6.0 mmol/l or&#xD;
      plasma glucose &lt;7.0 mmol/l Exclusion criteria&#xD;
&#xD;
        1. Age &gt;80 years.&#xD;
&#xD;
        2. Any concomitant disease or condition that may interfere with the possibility for the&#xD;
           patient to comply with or complete the study protocol.&#xD;
&#xD;
        3. Participant in an ongoing study.&#xD;
&#xD;
        4. Unwillingness to participate following oral and written information.&#xD;
&#xD;
      Endothelium-dependent vasodilatation is determined by venous occlusion plethysmography during&#xD;
      intra-arterial infusion of serotonin (21, 70 and 210 ng/min). Endothelium-independent&#xD;
      vasodilatation is determined by infusion of sodium nitroprusside (SNP; 1, 3 and 10 Âµg/min).&#xD;
      Each dose is given for 2 min at a rate of 2.5 ml/min.&#xD;
&#xD;
      Sixteen patients and age-matched healthy controls are included. On the day of the study the&#xD;
      subject arrives to the laboratory after having a light breakfast. Forearm vessels of the&#xD;
      non-dominant arm are cannulated and forearm blood flow is determined as described above.&#xD;
      Baseline endothelium dependent and endothelium independent vasodilatation is determined by&#xD;
      intra-arterial infusions of serotonin and SNP, respectively, during an intra-arterial&#xD;
      infusion of saline. Thereafter an intra-arterial infusion of the arginase inhibitor&#xD;
      N-omega-hydroxy-nor-l-arginine (nor-NOHA) is started and is maintained for 120 min at a rate&#xD;
      of 0.1 mg/min. The dose is based on a previous study by our group demonstrating improved&#xD;
      endothelial function. Endothelium-dependent and -independent vasodilatation is reassessed at&#xD;
      120 min of infusion.&#xD;
&#xD;
      Following determination of baseline endothelial function (poor glycemic control), the&#xD;
      patients are put on optimized glucose lowering therapy with insulin and/or oral glucose&#xD;
      lowering medication according to clinical routine at the day-care center of the department of&#xD;
      Endocrinology, Karolinska University Hospital for at least 8 weeks. Treatment target is mean&#xD;
      day blood glucose &lt;9 mmol/L and fasting blood glucose 4-6 mmol/L. After this,&#xD;
      endothelium-dependent and -independent vasodilatation before and following arginase&#xD;
      inhibition is re-assessed as described above.The healthy control group is only investigated&#xD;
      on one occasion.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 1, 2016</start_date>
  <completion_date type="Actual">July 31, 2019</completion_date>
  <primary_completion_date type="Actual">December 31, 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Endothelial function</measure>
    <time_frame>8 weeks</time_frame>
    <description>Change in endothelium-dependent dilatation</description>
  </primary_outcome>
  <enrollment type="Actual">16</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>serotonin</intervention_name>
    <description>Endothelium-dependent dilatation</description>
    <other_name>nitroprusside</other_name>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood samples&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Type 2 diabetes Healthy controls&#xD;
      </textblock>
    </study_pop>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Type 2 diabetes&#xD;
&#xD;
          2. Poor glycaemic control defined as a mean day blood glucose &gt;12 mmol/L.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Age &gt;80 years.&#xD;
&#xD;
          2. HbA1c &lt;70 mmol/mol&#xD;
&#xD;
          3. Myocardial infarction/unstable angina within 6 weeks prior to the study.&#xD;
&#xD;
          4. Treatment with oral anticoagulants (Warfarin or New oral anticoagulants)&#xD;
&#xD;
          5. Raynaud's phenomenon, peripheral vasculopathies, arterial shunting or other vascular&#xD;
             surgery of the study arm.&#xD;
&#xD;
          6. Any concomitant disease or condition that may interfere with the possibility for the&#xD;
             patient to comply with or complete the study protocol.&#xD;
&#xD;
          7. Participant in an ongoing study.&#xD;
&#xD;
          8. Unwillingness to participate following oral and written information.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Karolinska Institutet, Karolinska University Hospital</name>
      <address>
        <city>Stockholm</city>
        <zip>17176</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>March 20, 2018</study_first_submitted>
  <study_first_submitted_qc>March 26, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 29, 2018</study_first_posted>
  <last_update_submitted>February 19, 2020</last_update_submitted>
  <last_update_submitted_qc>February 19, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 21, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Karolinska Institutet</investigator_affiliation>
    <investigator_full_name>John Pernow</investigator_full_name>
    <investigator_title>professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nitroprusside</mesh_term>
    <mesh_term>Serotonin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

